HRP20211015T1 - Cjepivo protiv citomegalovirusa (cmv) - Google Patents
Cjepivo protiv citomegalovirusa (cmv) Download PDFInfo
- Publication number
- HRP20211015T1 HRP20211015T1 HRP20211015TT HRP20211015T HRP20211015T1 HR P20211015 T1 HRP20211015 T1 HR P20211015T1 HR P20211015T T HRP20211015T T HR P20211015TT HR P20211015 T HRP20211015 T HR P20211015T HR P20211015 T1 HRP20211015 T1 HR P20211015T1
- Authority
- HR
- Croatia
- Prior art keywords
- viral vector
- seq
- glycoprotein
- amino acid
- acid sequence
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10041—Use of virus, viral particle or viral elements as a vector
- C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
- C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361911135P | 2013-12-03 | 2013-12-03 | |
| US201462055699P | 2014-09-26 | 2014-09-26 | |
| EP14820762.4A EP3077519B1 (en) | 2013-12-03 | 2014-12-03 | Cmv vaccines |
| PCT/EP2014/076466 WO2015082570A1 (en) | 2013-12-03 | 2014-12-03 | Cmv vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211015T1 true HRP20211015T1 (hr) | 2021-10-01 |
Family
ID=52232138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211015TT HRP20211015T1 (hr) | 2013-12-03 | 2014-12-03 | Cjepivo protiv citomegalovirusa (cmv) |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10111945B2 (enExample) |
| EP (2) | EP3904522A1 (enExample) |
| JP (2) | JP6818551B2 (enExample) |
| CN (2) | CN115058452A (enExample) |
| AU (2) | AU2014359276B2 (enExample) |
| CA (1) | CA2932318C (enExample) |
| CY (1) | CY1124288T1 (enExample) |
| DK (1) | DK3077519T3 (enExample) |
| ES (1) | ES2868427T3 (enExample) |
| HR (1) | HRP20211015T1 (enExample) |
| HU (1) | HUE054579T2 (enExample) |
| LT (1) | LT3077519T (enExample) |
| PL (1) | PL3077519T3 (enExample) |
| PT (1) | PT3077519T (enExample) |
| RS (1) | RS61993B1 (enExample) |
| SI (1) | SI3077519T1 (enExample) |
| WO (1) | WO2015082570A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2604695T3 (pl) | 2007-12-27 | 2023-04-11 | Universität Zürich | Cząstka arenawirusa z defektem replikacji |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| DK3077519T3 (en) * | 2013-12-03 | 2021-06-14 | Hookipa Biotech Gmbh | Cmv-vacciner |
| HUE051390T2 (hu) | 2014-11-13 | 2021-03-01 | Univ Geneve | Háromszegmensû arenavírusok mint vakcinavektorok |
| EP3031822A1 (en) * | 2014-12-08 | 2016-06-15 | Novartis AG | Cytomegalovirus antigens |
| HK1246183A1 (zh) | 2015-06-10 | 2018-09-07 | Hookipa Biotech Gmbh | Hpv疫苗 |
| CA3002922A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| CN115948467A (zh) * | 2015-11-04 | 2023-04-11 | 霍欧奇帕生物科技有限公司 | 针对乙型肝炎病毒的疫苗 |
| CA3003548A1 (en) * | 2015-11-12 | 2017-05-18 | Hookipa Biotech Ag | Arenavirus particles as cancer vaccines |
| US11260090B2 (en) | 2016-03-08 | 2022-03-01 | University Of Vermont And State Agricultural College | Modified arenavirus |
| IL322403A (en) | 2016-04-15 | 2025-09-01 | Univ Pennsylvania | Preparations for the treatment of wet age-related macular degeneration |
| CA3041307A1 (en) * | 2016-10-21 | 2018-04-26 | Giuseppe Ciaramella | Human cytomegalovirus vaccine |
| JP2019533690A (ja) | 2016-11-04 | 2019-11-21 | ホオキパ バイオテック ジーエムビーエイチ | 癌ワクチンとしての複製欠損性アレナウイルス粒子及び３セグメント型アレナウイルス粒子 |
| CA3050914A1 (en) * | 2017-01-27 | 2018-08-02 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Vaccine compositions of herpesvirus envelope protein combinations to induce immune response |
| WO2018191666A1 (en) | 2017-04-14 | 2018-10-18 | Regenxbio Inc. | Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2 sulfatase (ids) produced by human neural or glial cells |
| WO2018204080A1 (en) * | 2017-05-02 | 2018-11-08 | The Scripps Research Institute | Compositions and methods related to arenavirus immunogens |
| US12558434B2 (en) | 2018-02-20 | 2026-02-24 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| CN112512569A (zh) * | 2018-05-11 | 2021-03-16 | 希望之城 | 表达多个巨细胞病毒(cmv)抗原的mva载体及其用途 |
| MX2021004273A (es) | 2018-10-17 | 2021-12-10 | Glaxosmithkline Biologicals Sa | Proteinas de citomegalovirus modificadas y complejos estabilizados. |
| KR102609106B1 (ko) * | 2018-12-10 | 2023-12-05 | 케이엠 바이올로직스 가부시키가이샤 | 사이토메갈로바이러스의 선천성 감염을 예방 또는 치료하기 위한 백신 |
| US20220380805A1 (en) | 2019-11-07 | 2022-12-01 | Universität Basel | Arenaviruses as vectors |
| EP4163378A4 (en) * | 2020-06-09 | 2024-03-13 | KM Biologics Co., Ltd. | Fusion protein of pentamer and gb of cytomegalovirus, and vaccine containing said fusion protein |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| RU2756557C1 (ru) * | 2020-11-02 | 2021-10-01 | Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГБУ "ВНИИЗЖ") | Способ опосредованного определения титра вируса ящура в неинактивированном сырье для вакцины при амплификации вирусной нуклеиновой кислоты и детекции РНК-ампликонов с применением технологии молекулярных биконов |
| WO2022173605A2 (en) | 2021-02-10 | 2022-08-18 | Regenxbio Inc. | Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) |
| US20240229073A1 (en) | 2021-05-13 | 2024-07-11 | Hookipa Biotech Gmbh | Arenaviruses as vectors |
| WO2024163912A2 (en) * | 2023-02-03 | 2024-08-08 | The Children's Medical Center Corporation | Vaccine and therapeutic protein delivery compositions comprising fusion proteins |
| AU2024343172A1 (en) | 2023-09-15 | 2026-03-05 | Gilead Sciences, Inc. | Arenavirus formulations, methods and uses thereof |
| CN118221773B (zh) * | 2024-02-05 | 2025-09-09 | 首都医科大学附属北京儿童医院保定医院 | 与HLA相关的CMV pp65表位疫苗组合物与应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| JP2607712B2 (ja) * | 1988-01-29 | 1997-05-07 | カイロン コーポレイション | 組換えｃｍｖ中和タンパク |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| ATE313560T1 (de) * | 2000-03-21 | 2006-01-15 | Genzyme Corp | Therapeutische anti-cytomegalovirus verbindungen |
| DE102004034461B4 (de) * | 2004-07-16 | 2008-02-07 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren |
| EP1856250B1 (en) * | 2005-02-15 | 2013-07-24 | The University of North Carolina At Chapel Hill | New live virus vaccines |
| US8063063B2 (en) | 2006-03-23 | 2011-11-22 | Novartis Ag | Immunopotentiating compounds |
| WO2007109813A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| PL2604695T3 (pl) * | 2007-12-27 | 2023-04-11 | Universität Zürich | Cząstka arenawirusa z defektem replikacji |
| US8580276B2 (en) * | 2009-06-05 | 2013-11-12 | City Of Hope | Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof |
| JP2012530500A (ja) * | 2009-06-26 | 2012-12-06 | ヴェクトライト バイオメディカ インコーポレイテッド | サイトメガロウイルス由来のペプチドを含む免疫原組成物および使用方法 |
| SG189176A1 (en) * | 2010-10-15 | 2013-05-31 | Glaxosmithkline Biolog Sa | Cytomegalovirus gb antigen |
| EP2664680A1 (en) * | 2011-01-07 | 2013-11-20 | Bioscience Slovakia | Antibody-based methods of diagnosing infections with lymphocytic choriomeningitis virus (LCMV) |
| WO2012162428A1 (en) | 2011-05-23 | 2012-11-29 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prime-boost vaccination for viral infection |
| EP3854413A1 (en) * | 2011-07-06 | 2021-07-28 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
| US8834307B2 (en) | 2011-10-06 | 2014-09-16 | Kawasaki Jukogyo Kabushiki Kaisha | Belt type continuously variable transmission |
| US20140348863A1 (en) * | 2011-10-12 | 2014-11-27 | Alessia Bianchi | Cmv antigens and uses thereof |
| GB2513768B (en) * | 2012-07-06 | 2015-04-15 | Novartis Ag | Complexes of cytomegalovirus proteins and nucleic acids encoding such proteins |
| ES2751423T3 (es) | 2013-03-15 | 2020-03-31 | Univ Geneve | Vacunas antimicobacterianas |
| DK3077519T3 (en) | 2013-12-03 | 2021-06-14 | Hookipa Biotech Gmbh | Cmv-vacciner |
| HUE051390T2 (hu) | 2014-11-13 | 2021-03-01 | Univ Geneve | Háromszegmensû arenavírusok mint vakcinavektorok |
| HK1246183A1 (zh) | 2015-06-10 | 2018-09-07 | Hookipa Biotech Gmbh | Hpv疫苗 |
| CN115948467A (zh) | 2015-11-04 | 2023-04-11 | 霍欧奇帕生物科技有限公司 | 针对乙型肝炎病毒的疫苗 |
| CA3003548A1 (en) | 2015-11-12 | 2017-05-18 | Hookipa Biotech Ag | Arenavirus particles as cancer vaccines |
| IL314272A (en) | 2016-05-18 | 2024-09-01 | Hookipa Biotech Gmbh | Three-segmented PICHINDE viruses as vaccine vectors |
| JP2019533690A (ja) | 2016-11-04 | 2019-11-21 | ホオキパ バイオテック ジーエムビーエイチ | 癌ワクチンとしての複製欠損性アレナウイルス粒子及び３セグメント型アレナウイルス粒子 |
| AU2018247958A1 (en) | 2017-04-07 | 2019-10-10 | Hookipa Biotech Gmbh | Arenavirus particles to treat solid tumors |
| US20220380805A1 (en) | 2019-11-07 | 2022-12-01 | Universität Basel | Arenaviruses as vectors |
| BR112022024404A2 (pt) | 2020-05-29 | 2023-02-07 | Hookipa Biotech Gmbh | Método para tratar câncer, sequência de nucleotídeos, célula hospedeira, partícula de lcmv, partícula de picv, composição farmacêutica, partícula de arenavírus |
-
2014
- 2014-12-03 DK DK14820762.4T patent/DK3077519T3/da active
- 2014-12-03 ES ES14820762T patent/ES2868427T3/es active Active
- 2014-12-03 PT PT148207624T patent/PT3077519T/pt unknown
- 2014-12-03 EP EP21165671.5A patent/EP3904522A1/en not_active Withdrawn
- 2014-12-03 WO PCT/EP2014/076466 patent/WO2015082570A1/en not_active Ceased
- 2014-12-03 HR HRP20211015TT patent/HRP20211015T1/hr unknown
- 2014-12-03 CA CA2932318A patent/CA2932318C/en active Active
- 2014-12-03 CN CN202210602284.6A patent/CN115058452A/zh active Pending
- 2014-12-03 SI SI201431830T patent/SI3077519T1/sl unknown
- 2014-12-03 US US15/101,363 patent/US10111945B2/en active Active
- 2014-12-03 CN CN201480074709.4A patent/CN105980570B/zh active Active
- 2014-12-03 PL PL14820762T patent/PL3077519T3/pl unknown
- 2014-12-03 HU HUE14820762A patent/HUE054579T2/hu unknown
- 2014-12-03 AU AU2014359276A patent/AU2014359276B2/en active Active
- 2014-12-03 RS RS20210759A patent/RS61993B1/sr unknown
- 2014-12-03 LT LTEP14820762.4T patent/LT3077519T/lt unknown
- 2014-12-03 JP JP2016536893A patent/JP6818551B2/ja active Active
- 2014-12-03 EP EP14820762.4A patent/EP3077519B1/en active Active
-
2018
- 2018-09-20 US US16/137,323 patent/US11554169B2/en active Active
-
2020
- 2020-12-28 JP JP2020218641A patent/JP7001807B2/ja active Active
-
2021
- 2021-04-26 AU AU2021202541A patent/AU2021202541A1/en not_active Abandoned
- 2021-06-29 CY CY20211100578T patent/CY1124288T1/el unknown
-
2022
- 2022-11-22 US US18/058,116 patent/US20230181725A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN105980570B (zh) | 2022-06-07 |
| DK3077519T3 (en) | 2021-06-14 |
| CN105980570A (zh) | 2016-09-28 |
| CY1124288T1 (el) | 2022-07-22 |
| WO2015082570A1 (en) | 2015-06-11 |
| SI3077519T1 (sl) | 2021-07-30 |
| LT3077519T (lt) | 2021-04-26 |
| HUE054579T2 (hu) | 2021-09-28 |
| JP6818551B2 (ja) | 2021-01-20 |
| US20230181725A1 (en) | 2023-06-15 |
| PT3077519T (pt) | 2021-05-13 |
| PL3077519T3 (pl) | 2021-10-18 |
| WO2015082570A8 (en) | 2015-11-26 |
| US11554169B2 (en) | 2023-01-17 |
| RS61993B1 (sr) | 2021-07-30 |
| US20160296619A1 (en) | 2016-10-13 |
| AU2014359276A1 (en) | 2016-06-16 |
| JP2017503482A (ja) | 2017-02-02 |
| JP7001807B2 (ja) | 2022-02-04 |
| EP3904522A1 (en) | 2021-11-03 |
| US20190247493A1 (en) | 2019-08-15 |
| US10111945B2 (en) | 2018-10-30 |
| CA2932318A1 (en) | 2015-06-11 |
| AU2021202541A1 (en) | 2021-05-27 |
| ES2868427T3 (es) | 2021-10-21 |
| JP2021061848A (ja) | 2021-04-22 |
| EP3077519B1 (en) | 2021-03-31 |
| HK1226440A1 (zh) | 2017-09-29 |
| CA2932318C (en) | 2023-10-10 |
| EP3077519A1 (en) | 2016-10-12 |
| AU2014359276B2 (en) | 2021-01-28 |
| CN115058452A (zh) | 2022-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211015T1 (hr) | Cjepivo protiv citomegalovirusa (cmv) | |
| JP2017503482A5 (enExample) | ||
| JP2021061848A5 (enExample) | ||
| Vander Veen et al. | Alphavirus replicon vaccines | |
| Rühl et al. | Vaccination against the Epstein–Barr virus | |
| FI3371316T3 (fi) | Rokotteita hepatiitti b -virusta vastaan | |
| JP2021182922A5 (enExample) | ||
| Murrell et al. | Genetic stability of bacterial artificial chromosome-derived human cytomegalovirus during culture in vitro | |
| Wang | Nonhuman primate models for Epstein-Barr virus infection | |
| HRP20201684T1 (hr) | Tri-segmentirani arenavirusi kao vektori cjepiva | |
| Brennan et al. | Mapping of transcription termination within the S segment of SFTS phlebovirus facilitated generation of NSs deletant viruses | |
| Small et al. | Viruses—From pathogens to vaccine carriers | |
| JP2017510262A5 (enExample) | ||
| JP2019511921A5 (enExample) | ||
| Shoji et al. | Generation and characterization of P gene-deficient rabies virus | |
| Morimoto et al. | Characterization of P gene-deficient rabies virus: propagation, pathogenicity and antigenicity | |
| Gutiérrez-Álvarez et al. | Middle East respiratory syndrome coronavirus vaccine based on a propagation-defective RNA replicon elicited sterilizing immunity in mice | |
| JP5675789B2 (ja) | 免疫接種のための発現ベクターとしての水疱性口内炎ウイルスの異なる複数の抗原型 | |
| CN113930452A (zh) | 基于黑猩猩腺病毒载体的重组载体、腺病毒、2019新型冠状病毒疫苗及其制备方法 | |
| Erdman et al. | Alphavirus replicon particle vaccines developed for use in humans induce high levels of antibodies to influenza virus hemagglutinin in swine: proof of concept | |
| Zhang et al. | A novel inactivated bivalent vaccine for chickens against emerging hepatitis-hydropericardium syndrome and infectious bursal disease | |
| Hidmark et al. | Humoral responses against coimmunized protein antigen but not against alphavirus-encoded antigens require alpha/beta interferon signaling | |
| CN104195154B (zh) | 新城疫病毒Mukteswar中等毒力疫苗株反向遗传操作系统及其应用 | |
| CN106574253A (zh) | 用于快速制备减活rna病毒的方法 | |
| Zhang et al. | EBV Vaccines in the prevention and treatment of nasopharyngeal carcinoma |